Roles
- Professor
- Chief, Division of Myeloma, Department of Medicine
- Director, Sylvester Myeloma Institute
- Co-Leader, Translational and Clinical Oncology Program
- Paul J. DiMare Endowed Chair in Immunotherapy
-
Biography
I am Professor of Medicine, Chief of the Myeloma Division, and Co-Leader of the Translational and Clinical Oncology (TCO) Program at NCI-designated Sylvester Comprehensive Cancer Center (Sylvester). In my Co-Leader role, I work closely with Dr. Jaime Merchan to oversee the clinical and research operations for TCO as well as the development of the research program. Dr. Merchan and I complement each other's talents and strengths and serve as key conduits to move science from the lab into the clinic, and vice versa. As a Cancer Center Support Grant member, I participate in research activities as an independent investigator, as a leader of research governance committees, and I serve on multi-disciplinary research teams.
I am a frequent speaker and faculty member for national and international meetings on myeloma and hematologic malignancies. I am on the editorial board for Hemasphere, Leukemia, and Blood Advances and serve as a reviewer for grants and for several high-impact journals. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Teaching Interests
I am a frequent speaker and faculty member for national and international meetings on myeloma and hematologic malignancies. I also participate in medical education through mentoring and teaching of medical students, PhD students, fellows, post-docs, and junior faculty. -
Research Interests
Over the past several years, I have designed and conducted a series of studies to define biological mechanisms of multiple myeloma (MM) and the transformation from myeloma precursor disease (monoclonal gammopathy of undetermined significance [MGUS] and smoldering myeloma) to MM. We continue to model and integrate clinical, immune microenvironment, and genomic data to better characterize the pathogenesis and (sub)clonal evolution of MM and its precursor disease to better evaluate the mutagenic impact of different chemotherapeutic agents and to improve clinical outcomes. Our group has strong expertise in both clinical and genome profiling analysis. In addition, we have a proven track record on the development of high-throughput laboratory and analytical pipelines (including bioinformatics, statistical modeling, and artificial intelligence (AI)), and we have the skills and experience on how to integrate large and complex genomic datasets.
For more than a decade, I have launched several early-intervention clinical trials for patients with high-risk smoldering myeloma, with the aim to delay or prevent transformation. Furthermore, as part of my interest in effective, non-intense therapies, I have designed clinical studies to seek rapid and deep responses in patients with smoldering myeloma as well as newly diagnosed MM. Beyond traditional clinical criteria for complete remission, I have developed novel strategies to define minimal residual disease (MRD) detection post-therapy in MM and in patients with related disorders, using cell-, molecular-, and imaging-based methods. My goal is to define sensitive MRD methods that can be used for longitudinal monitoring without the need for invasive biopsies. The intention is to use AI to integrate these data with genomic, demographic, clinical, and therapeutic features to develop individualized prognostication, to redefine the concept of high-risk disease, and to design, for the first time, patient-tailored therapeutic strategies. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.Professional Activities
Clinical Trials
Viewing 0 of 18 clinical trials.
-
The purpose of this study is to continue providing access to elranatamab and to gain additional safety data on this study drug.
- Principal Investigator: Carl Landgren
- Study Phase: Phase IV
- Enrollment Status: Open
-
To evaluate the side effects and anti-tumor activity of PF-07994525 in people with Multiple Myeloma
- Principal Investigator: Carl Landgren
- Study Phase: Phase I
- Enrollment Status: Open
-
Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs Carfilzomib, Lenalidomide, and Dexamethasone vs Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
- Principal Investigator: Carl Landgren
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma: Phase 2 Trial of Clinical Applications
- Principal Investigator: Carl Landgren
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant
- Principal Investigator: Carl Landgren
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (BCMA) CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH OTHER ANTI-CANCER TREATMENTS IN PARTICIPANTS WITH MULTIPLE MYELOMA
- Principal Investigator: Carl Landgren
- Study Phase: Phase 2
- Enrollment Status: Closed
-
The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab in combination with pomalidomide and dexamethasone (DPd).
- Principal Investigator: Carl Landgren
- Study Phase: Phase III
- Enrollment Status: Closed
-
C1071020 is a Phase 1b, open-label, prospective, multi-center, study to evaluate safety,efficacy, PK, and pharmacodynamics of elranatamab (PF-06863135) in combination withcarfilzomib plus dexamethasone (Part 1) and elranatamab in combination with PF-07901801(previously referred to as TTI-622) (Part 2A and 2B) in participants with RRMM. Studyendpoints will be evaluated using a dose escalation approach.
- Principal Investigator: Carl Landgren
- Study Phase: Phase I
- Enrollment Status: Open
-
The purpose of this study is to evaluate whether the BCMA-CD3 bispecific antibody elranatamab, alone and/or in combination with the anti-CD38 monoclonal antibody, daratumumab, can provide more benefit to people with multiple myeloma compared to a combination therapy including daratumumab, pomalidomide, and dexamethasone. People with multiple myeloma who have received previous treatment including lenalidomide and a proteasome inhibitor will be enrolled in the study. Part 1 of the study will assess the safety and activity of different doses of elranatamab in combination with daratumumab. People participating in Part 2 of the study will be randomly assigned to receive either elranatamab alone, elranatamab plus daratumumab, or daratumumab, pomalidomide, and dexamethasone. Part 2 will compare the safety and activity of (1) elranatamab alone compared to daratumumab, pomalidomide, and dexamethasone, and (2) elranatamab plus daratumumab compared to daratumumab, pomalidomide, and dexamethasone. Participants in both parts of the study will receive study treatment until their disease progresses, they experience unacceptable side effects, or they choose to no longer participate in the study.
- Principal Investigator: Carl Landgren
- Study Phase: Phase III
- Enrollment Status: Open
-
To compare the efficacy of elranatamab (Arm A) vs EPd or PVd or Kd (Arm B). To determine the safety and tolerability of elranatamab monotherapy.
- Principal Investigator: Carl Landgren
- Study Phase: Phase III
- Enrollment Status: Open
-
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.
- Principal Investigator: Carl Landgren
- Study Phase: Phase III
- Enrollment Status: Open
-
Evaluate the rate of deep remissions (10-5 sensitivity) in newly diagnosed participants with multiple myeloma receiving the ERd combination treatment
- Principal Investigator: Carl Landgren
- Study Phase: Phase II
- Enrollment Status: Open
-
An Open-label, First-in-human, Single Agent, Dose Escalation Study for the Evaluation of Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR442257 in Patients With Relapsed and Refractory Multiple Myeloma and Relapsed and Refractory Non-Hodgkin Lymphoma
- Principal Investigator: Carl Landgren
- Study Phase: Phase 1
- Enrollment Status: Closed
-
A Phase I Dose Escalation Study of NMS-03597812, a PERK Inhibitor, in Adult Patients With Relapsed or Refractory Multiple Myeloma
- Principal Investigator: Carl Landgren
- Study Phase: Phase 1
- Enrollment Status: Closed
-
This study will investigate ABBV-453 beginning at 160 mg and follow a 2-step dose escalation strategy up to 240 mg and 320 mg to identify the MTD. Dose escalation will be guided by a Bayesian optimal interval (BOIN) design based on the cumulative number of subjects who experience a DLT at a given ABBV-453 dose level.
- Principal Investigator: Carl Landgren
- Study Phase: Phase I
- Enrollment Status: Closed
-
The purpose of this study is to find out whether a dietary approach that includes prolonged overnight fasting, guided by a Mediterranean-style eating pattern, is feasible for patients with myeloma precursor disease or newly diagnosed multiple myeloma.
- Principal Investigator: Carl Landgren
- Study Phase: N/A
- Enrollment Status: Open
-
The purpose of this study is to compare the efficacy of teclistamab with PVd/Kd.
- Principal Investigator: Carl Landgren
- Study Phase: Phase III
- Enrollment Status: Not Accepting
-
The purpose of this research study is to see if a combination of teclistamab and daratumumab will have any benefits at dose levels researchers found acceptable in earlier studies. The researchers want to find out the effects (good and bad) the combination of teclistamab and daratumumab has on you and your condition.
- Principal Investigator: Carl Landgren
- Study Phase: Phase II
- Enrollment Status: Open
